Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Peloruside- and laulimalide-resistant human ovarian carcinoma cells have βI-tubulin mutations and altered expression of βII- and βIII-tubulin isotypes.

Molecular cancer therapeutics - 1 Aug 2011

Kanakkanthara Arun, Wilmes Anja, O'Brate Aurora, Escuin Daniel, Chan Ariane, Gjyrezi Ada, Crawford Janet, Rawson Pisana, Kivell Bronwyn, Northcote Peter T, Hamel Ernest, Giannakakou Paraskevi, Miller John H

Abstract excerpt

Peloruside A and laulimalide are potent microtubule-stabilizing natural products with a mechanism of action similar to that of paclitaxel. However, the binding site of peloruside A and laulimalide on tubulin remains poorly understood. Drug resistance in anticancer treatment is a serious problem. We developed peloruside A- and laulimalide-resistant cell lines by selecting 1A9 human ovarian carcinoma cells that...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Bridged Bicyclo Compounds, Heterocyclic

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Resistance, Neoplasm

Share to Lactones

Share to Macrolides

Share to Ovarian Neoplasms

Share to Protein Multimerization

Share to Tubulin

Source

Open in PubMed Open full text

Identifiers

PMID: 21653684
DOI: 10.1158/1535-7163.MCT-10-1057
PMCID: PMC3158586

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Peloruside- and laulimalide-resistant human ovarian carcinoma cells have βI-tubulin mutations and altered expression of βII- and βIII-tubulin isotypes.PMID 21653684Read ↗

Resistance to peloruside A and laulimalide: functional significance of acquired βI-tubulin mutations at sites important for drug-tubulin binding.Semantic proximity Read ↗

βII-tubulin and βIII-tubulin mediate sensitivity to peloruside A and laulimalide, but not paclitaxel or vinblastine, in human ovarian carcinoma cells.Semantic proximity Read ↗

βI-tubulin mutations in the laulimalide/peloruside binding site mediate drug sensitivity by altering drug-tubulin interactions and microtubule stability.Semantic proximity Read ↗

Mutations in the β-tubulin binding site for peloruside A confer resistance by targeting a cleft significant in side chain binding.Semantic proximity Read ↗

Peloruside A does not bind to the taxoid site on beta-tubulin and retains its activity in multidrug-resistant cell lines.Semantic proximity Read ↗

Characterizing the laulimalide-peloruside binding site using site-directed mutagenesis of TUB2 in S. cerevisiae.Semantic proximity Read ↗

Cancer cells acquire mitotic drug resistance properties through beta I-tubulin mutations and alterations in the expression of beta-tubulin isotypes.Semantic proximity Read ↗

Peloruside A: a lead non-taxoid-site microtubule-stabilizing agent with potential activity against cancer, neurodegeneration, and autoimmune diseaseSemantic proximity Read ↗

Structural insight into the role of Gln293Met mutation on the Peloruside A/Laulimalide association with αβ-tubulin from molecular dynamics simulations, binding free energy calculations and weak interactions analysis.Semantic proximity Read ↗

Mutations in beta-tubulin map to domains involved in regulation of microtubule stability in epothilone-resistant cell lines.Semantic proximity Read ↗

A Tale of Two Tumor Targets: Topoisomerase I and Tubulin. The Wall and Wani Contribution to Cancer ChemotherapySemantic proximity Read ↗

Mechanisms of Tubulin Binding Ligands to Target Cancer Cells: Updates on their Therapeutic Potential and Clinical TrialsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.